Limited Genetic Testing Access Delays Alagille Diagnosis for Asian Girl

Limited access to confirmatory genetic testing in low- and middle-income countries may significantly delay the diagnosis of Alagille syndrome in children, potentially leading to misdiagnoses and unwarranted surgical procedures, according to reporting by Liver Disease News.

Alagille syndrome is a rare genetic disorder characterized by abnormalities in embryonic development that result in a reduced number of bile ducts. This condition causes cholestasis, a state where the flow of bile from the liver to the intestines is impaired. When bile accumulates in the liver and leaks into the bloodstream, it can lead to liver damage and symptoms including jaundice and itching.

The Risk of Misdiagnosis

In resource-poor settings where genetic studies are unavailable, clinicians must rely on diagnostic clinical criteria. These include identifying characteristic facial features, heart or bone abnormalities, eye issues, and a reduced number of bile ducts observed during a liver biopsy.

Because these clinical signs can overlap with other conditions, there is a high risk of confusion with biliary atresia, another infantile condition marked by cholestasis where bile ducts are either absent or blocked. Researchers noted that in settings with limited genetic testing, Alagille syndrome may be misdiagnosed as … biliary atresia.

Such misdiagnoses are critical because the treatments for biliary atresia and Alagille syndrome differ. Misidentifying the condition can lead to patients undergoing surgeries that are not indicated for Alagille syndrome.

Clinical Data and Manifestations

The challenges of diagnosing the syndrome were highlighted in a study published in the Sudanese Journal of Paediatrics, titled Presentation and outcome of Alagille syndrome in paediatric patients at State Academic Hospital in South Africa. The researchers conducted a retrospective analysis of medical records for 25 children diagnosed with the syndrome at a specialized liver clinic between 1992 and 2020.

The study found that 72% of the children developed symptoms before the age of one. While all patients showed a reduced number of bile ducts on liver biopsy, the manifestations varied across the group:

• Cholestasis: 96%
• Characteristic facial features: 80%
• Heart defects: 64%
• Bone issues: 40%
• Eye problems: 36%
• Kidney disease: 32%

Regarding liver-related complications, 84% of the children experienced itching, and 60% developed high blood pressure in the portal vein. 32% had xanthomas, which are waxy, yellowish fatty deposits under the skin.

Laboratory markers also indicated significant liver stress. All children in the study had elevated alkaline phosphatase (ALP) levels. High levels of conjugated bilirubin were found in 92% of patients, and gamma-glutamyl transferase (GGT) was elevated in 84%.

Genetic Drivers and Diagnostic Standards

Alagille syndrome is most commonly caused by mutations in the JAG1 or NOTCH2 genes. Under standard medical guidelines, a diagnosis is typically confirmed if a patient presents at least three of five to seven major signs and symptoms.

However, the threshold for diagnosis is lower if there is a positive genetic test or a known family history of the disease. The absence of these testing capabilities in certain regions forces a reliance on the more complex and potentially ambiguous clinical criteria, increasing the likelihood of diagnostic delays.